Table 1.
Biological activities and physicochemical properties of series 4 and 5
![]() | ||||||||||
R1 | R3 | IC50 (µM)a Mer TK |
GI50 (µM)b | Propertiesc | ||||||
---|---|---|---|---|---|---|---|---|---|---|
A549 | KB | KB-vin | DU145 | MV4-11 | Aq. Sol. (µ g/mL) |
Log P | ||||
4a | ![]() |
H | 1.08 | 10.1 | 11.1 | 12.6 | 12.4 | 4.91 | 10.4 | >5 |
5a | ![]() |
Me | 1.14 | 9.4 | 11.7 | 10.1 | 10.2 | 2.70 | 1.11 | >5 |
4b | ![]() |
H | 0.68 | 15.2 | 20.3 | 17.1 | 18.3 | 8.75 | 95.6 | 2.54 |
5b | ![]() |
Me | 2.01 | 13.0 | 24.8 | 30.8 | 30.2 | 70.1 | ND | ND |
4c | ![]() |
H | 3.43 | 3.53 | 5.33 | 5.09 | 4.08 | 5.88 | 4.36 | >5 |
5c | ![]() |
Me | 1.84 | 12.4 | 13.7 | 12.4 | 13.0 | 2.33e | 3.43 | >5 |
4d | ![]() |
H | 2.25 | 16.1 | 14.8 | 17.5 | 14.3 | 3.07 | 6.61 | 3.21 |
5d | ![]() |
Me | 10.2 | 19.9 | 18.7 | 22.9 | 24.3 | ND | ND | ND |
4e | ![]() |
H | 2.06 | 20.1 | 21.0 | 15.3 | 20.1 | ND | ND | ND |
5e | ![]() |
Me | >30 | NDd | ND | ND | ND | ND | ND | ND |
4f | ![]() |
H | 3.56 | 13.0 | 13.3 | 13.4 | 13.0 | <13.4 | ND | ND |
5g | ![]() |
Me | >30 | ND | ND | ND | ND | ND | ND | ND |
Staurosporinef | 0.00081 | |||||||||
Paclitaxel (nM)f | 4.9 | 2.6 | 948 | 2.6 | ND |
The concentration that inhibits 50% Mer tyrosine kinase;
The concentration inhibits 50% human tumor cell growth, averaged values determined by at least three independent experiments;
active compounds with IC50 <10 µM and GI50 <20 µM were measured by the methods in Reference 19;
not detected;
tested in human chronic myelogenous leukemia (K526) cells;
reference compounds as the passitive control in related assays.